Suppository Chelation Protocol
Journal of Advancement in Medicine
Volume 2, Numbers 1/2, Spring/Summer 1989
Ninety Percent Reduction in Cancer Mortality after Chelation Therapy With EDTA
Walter Blumer, M.D. and Elmer Cranton, M.D.
ABSTRACT: Mortality from cancer was reduced 90% during an 18-year follow-up of 59 patients treated with Calcium-EDTA. Only one of 59 treated patients (1.7%) died of cancer while 30 of 172 non treated control subjects (17.6%) died of cancer (P=0.002). Death from artherosclerosis was also reduced. Treated patients had no evidence of cancer at the time of entry into this study. Observations relate only to long-term prevention of death from malignant disease, if chelation therapy is begun before clinical evidence of canceroccurs. Control and treated patients lived in the same neighborhood, adjacent to a heavyily traveled highway in a small Swiss city. Both groups were exposed to the same amount of lead from automobile exhaust, industrial pollution and other carcinogens. Exposure to carcinogens was no greater for the studied population than exists in most other metropolitan areas throughout the world. Statistical analysis showed EDTA chelation therapy to be the only significant difference between controls and treated patients to explain the marked reduction in cancer mortality.
Edta is well recognized as a therapy for lead toxicity. EDTA also removes other toxic heavy metals and nutritional elements such as iron which promote cancer by catalyzing free radical pathology.
Lead from automobile exhausts, petrochemicals form wear of automobile
tires, cadmium, and other carcinogens are present in higher concentrations
adjacent to heavily traveled automobile highways.
These substances cause cancer and potentate other carcinogens.
It was reported in an earlier paper that cancer mortality among 231
adults living along a heavily traveled highway was higher than among persons
living in a traffic-free section of the same city1
Nervous disorders, headaches, fatigue, gastrointestinal disorders,
depression, and substance abuse was also observed with higher frequency.2
It was postulated that lead exposure from automobile exhausts might
be one cause of this difference.
Beginning in 1961, a group of 59 patients with such symptoms was treated
with parenteral doses of Calcium EDTA. Symptoms
improved and urinary delta-amino levulinic acid diminished.3
Subsequent to the EDTA chelation therapy, a decrease in cancer mortality
was observed. When compared with a
control group of untreated patients who did not receive EDTA, many fewer cancer
deaths were recorded,4,5.
The control group was similar to the treated group in all ways except to
the EDTA chelation therapy.
The purpose of this present study is to determine more precisely and to
statistically analyze the long-term change in cancer mortality after treatment
with EDTA>
Statistical Data
A group of 231 adults was studied beginning in late 1958.
All resided along the main highway in a small Swiss city with a total population
of approximately 3,000. Of
these 231 people (105 men and 126 women), 31 persons, (17 men and 14 women) died
of malignant tumors during the 18-year observation period (1959-1976).
Causes of death included 4 cases of bronchogenic carcinoma, 5 of colon
carcinoma, 5 of gastric carcinoma, 2 of beast cancer, 3 of ovarian carcinoma, 1
of pancreatic carcinoma, 2 of pleural endothelioma, and 9 cases of other types
of cancer. In all but one case,
histopathological diagnosis was confirmed by a hospital pathologist.
Twenty-eight of the deceased individuals had lived for 10 or more years
directly adjacent to the highway and most were normally present in their homes
for 24 hours of every day.
Fifty-nine adult study patient received ten or more injections of 1.9 gm
calcium EDTA plus vitamins C and B1
From 1959 through 1976, only one (1.7%) of patients treated with EDTA
died from cancer. In comparison, of
172 untreated control subjects who had not received calcium EDTA, 30 (17.4%)
died from cancer. This represents a
ten-fold greater incidence of cancer mortality in untreated persons (P=0.002).
The two groups were similar in all other respects.
The treated group consisted of 35 women and 24 men.
It was initially thought that this higher percentage of women may have
included fewer smokers which might partially explain the reduced mortality.
Analysis showed that none of the 35 treated women died of cancer.
Of 91 untreated women, 14 died of cancer, an incidence of 15%, and all
female cancer deaths occurred in nonsmokers.
The treated group did not include a greater proportion of persons who
were less exposed to carcinogens in their occupations or who spent more time
away from the heavily congested highway during the day.
Analysis of occupational data and location during the day showed no
differences between the two groups. Housewives, the majority of whom remained at
home each day, were represented equally in both groups.
No significant differences existed in age distribution between treated
patients and controls. There were
no significant socio-economic differences between the treated and the untreated
persons. Cancer mortality was
independent of monetary income.
Laboratory Analysis
Increased urinary lead excretion after injection of EDTA
is a recognized test for lead accumulation in the body.6 Urinary lead
excretion was measured before and after EDTA infusion in 5 patients with atomic
absorption spectroscopy,7 using the method of Roosels.8
In every case, a substantial increase in lead excretion was measured.
Simultaneously, urinary delta-amino levulinic acid (DALA) decreased.
DALA was measured in the Central Laboratories of the University Hospital
of Zurich, according to the methods of Doss and Schmidt.9
It is
emphasized that the population studied and reported on in this paper was not
exposed to any more lead or other environmental carcinogens than residents of
most metropolitan areas throughout the world.
Traffic flow past residences of the study subjects was 4000 vehicles per
day in 1956, increasing to 8000 vehicles per day in 1968.
Of those, 7000 were passenger cars and 400 were diesel trucks.
Environmental measurements of pollutants and carcinogens were made in the
immediate and surrounding area of this study.
Tests were done at the Woods Hole Laboratories, Massachusetts, USA, using
ultraviolet spectrophotography, mass-spectrography and chromatography.10
Soil tests adjacent to the highway where the study population lived
showed the presence of polycyclic aromatic hydrocarbons, which are known
carcinogens. In more remote
sections of the same city, levels of these pollutants were found to be
approximately three times lower, inversely correlated with the distance from
automobile traffic. Further
analyses showed the majority of measured carcinogens to be from automobile
pollution. Pollution immediately
adjacent to the highway where the study population resided was at or only
slightly above permissible levels allowed under public health and environmental
regulations in the USA.
Discussion
Following preliminary communication of these data, the
committee responsible for the surveillance of air quality in Switzerland
scrutinized the results using a different statistical method.11
They found a higher incidence of death from cancer in the
untreated group than in the population of Switzerland as a whole.
The fact that an identical
group treated with EDTA experienced a 90% reduction in cancer mortality, as well
as a reduction in death from all causes was also confirmed.
The fact that the general mortality as well as cancer mortality was lower
in treated than untreated individuals was also confirmed by Knutti and
Schlatter.11 Their
proposed explanation was that treated patients might possibly have been more
health conscious or under better medical care, but this does not seem an
adequate explanation of the recorded facts.
Residents of less polluted areas experience a lower cancer mortality,
despite the same level of medical care.
Evidence presented in this paper indicated that (1) EDTA removes
cancer causing or promoting substances, from the body, and (2) those substances
are correlated with environmental pollution from vehicular traffic.
The overall reduction of death from all causes and increased Longevity I
the EDTA treated group shows that chelation therapy also reduces other common
causes of mortality such as artherosclerosis and cardiovascular disease.
Except for cancer mortality, exact data are not available for statistical
analysis.
As early as 1961, it was reported from animal experiments that
intravenous injections of EDTA could slow the growth of experimental carcinoma 12.
A cancer-inhibiting effect has also been demonstrated for other chelating
agents, including BAL, cystine, penicillamine and citric acid 13-16.
Many tumor inhibiting medications, including 5-flouracil, possess
metal-binding properties. 17
Lead
potentiates the carcinogenicity of aromatic hydrocarbons such as benzopyrene by
five fold. 18 areas adjacent to heavily traveled highways are polluted with many
other carcinogens, including polycyclic aromatic hydrocarbons, nitrosamines,
epoxides, cadmium and asbestos, in addition to inorganic and tetraethyl lead.
Since the data from this study were last reported,5 new
research has linked cancer to free radical pathology. 19-21.
EDTA removes transition elements, such as iron, which accelerate free
radical pathology, including cancer. Iron
is an essential nutritional element but it is also know to accumulate with age.
Catalysis of lipid peroxidation by iron potentiates the cancer promoting
substances. EDTA increases the
urinary excretion of unbound and freely catalytic iron 10 times more then it
does lead. There are many reasons
why EDTA chelation therapy could act to prevent cancer.
A recent publication by McDonagh, et al, 22 confirms
improvement in a wide variety of symptoms, as first reported in this study
population.2 Neurasthenic and nonspecific multi-organ symptoms improve
significantly following EDTA chelation therapy, resulting in a marked
improvement in the overall quality of life.
Body stores of iron correlate with the risk of cancer.23-25
and artherosclerosis. 26 EDTA removes unbound and potentially toxic
iron from the body much more effectively than lead, 21 which may
account for the findings in this study.
Large
scale, double blind, controlled studies should be undertaken to fully document
the many benefits observed in clinical practice following treatment with EDTA.
EDTA is an inexpensive and relatively safe substance to administer but he
patent has expired and pharmaceutical companies have no incentive to fund such
research.
References
1. Blumer W. Jaumann R, Reich T: Morotsierungwichtigste
ursung? Praxis 1972
2.. Blumer W: Nervose Storungen durch autoabgase. Praxis
1970; 59: 1809-1816.
3. Blumer W, Reich T: Gesundheitsschadigung durch
bleibenzin. Praxis 1975;64:261-265.
4. Blumer W, Riech T: Bleibenzin und krebsmortalitat. Schweit
med Wschr 1976; 106:503-506.
5. . Blumer W,
Reich T: Leaded gasoline - a cause of cancer. Envirnmental
International, 1980; 3: 465 - 71.
6. Moeschlin S: Klinik und Therapie der
Vergiftungen. Stuttgart, George Thieme Verlag, 1965.
7. Blumer W: Bleidepots bei anwohnern einer autostrasse.
Med Neuheiten June 1969; 75:3-8.
8. Roosels D: An atomic absorption determination of lead
in urine after extraction with dither. Atom Abscam Newsweek 1968; 7:9-10.
9. Doss M, SchmidtA: Quantatative bestmtimmung
vonrphobilinogen im urin mit ionenaustauchchromatographie-fertigsaulen.
Z klin Chem klin Biochem 1971;9:99-102.
10. Blumer M, Blumer W, Reich T: Polycyclic aromatic
hydrocarbons in soils of a mountain valley: Correlation with highway traffic and
cancer incidence. Envir Sci Technol 1977;11: 1082-1084.
11. Knutti R, Schlatter C: Motorisierung und
Krebsgefahrdung. Schweiz med Wschr. 1977; 107:312
12. Balmus G, Nastac E, Sandulesco T: L'action d'un
produit chelateur. Le calciethylaminediaminetetracetate disodique sur
l'evolution du carcinome T8 Guerin chez le rat. Rev Path gen 1961;61:
423-433.
13. Apffel CA, Walker JE, Issarescu S: Tumor rejection in
experimental animals treated with radioprotective thiols. Cancer Res
1975; 35:429-37.
14.Kallistratos G: Verhinderung der
3,4-Benzopyren-Kanzerogenese durch naturliche und synthetische Verbindungen. Munch
med Wschr 1975;117:391-394.
15. Leuchtenberger C, Leuchtenberger R, Zbinden I, Schleh
E: SH reactivity of cigarette smoke and its correlation with carcinogenic
effects on hamster lung cultures. Z Soz Prav med 1976;21:47-50.
16. Mizrah IJ, Emmelot P: The effectt of cysteine in the
metabolich changes produced by two carcinogenic n-nitrosodialkylamines in rat
liver. Cancer Res 1962; 22:339-351.
17. FurstA: Chelation and cancer - a speculative review,
in Seven MJ, Johnson LA (eds): Metal Binding in Medicine. Philadelphia,
J B Lipincott, 1960, pp 336 - 344.
18. Dehnen W, Monch W, BrockhausA: Beeinflussung
desAbbhaus von Benz(a)pyren in der Lunge durch Schwermetalle, in Girardet W 9ed)
Lufthygiene und Silikoseforschung. Jahresbericht 1976, Band 9, W
Girardet Ed., Essen 231.
19. Demopoulos HB, Peitronigro DD, Flamm ES, Seligman ML:
The possible role of free radical reactions in carcinogenisis. Journal of
Environmental Pathology and Toxicology. 1980;3:273 - 303.
20. Demopoulos HB, Peitronigro DD, Seligman ML: The
development of secondary pathlogy with free radical reactions as a threshold
mechanism. Journal of the American College of Toxicology.
1983; 2(3):173-84.
21. Cranton EM, Frackelton JP: Free radical pathology in
age-associated diseases: Treatment with EDTA chelation, nutrition and
antioxidants. Journal of Holistic Medicine 1984; 6 (1) :6-37.
22. McDonaugh EW, Rudolph CJ, Cheraskin E: The
"clinical change" in patients treated with EDTA chelation plus
multivitamin/trace mineral supplementation. Journal of Orthomolecular
Psychiatry 1985; 14(1): 61-65.
23. Stevens RG, Jones DY, Micozzi MS, et al: Body iron
stores and the risk of cancer in Taiwan. JNCI 1988;319:1047-1052..
24. Stevens RG, Beasley RP, Blumberg BS: Iron binding
proteins and risk of cancer in Taiwan. Jnci 1986;76:605-610.
25.Selby JV, Friedman GD: Epidemiologic evidence of an
association between body iron stores and risk of cancer. Int J
Cancer 1988; 41 677-682.
26. Sullivan JL: Iron and the sex difference in heart
disease risk. Lancet 1981;1:1283-1294.
